{
    "nct_id": "NCT04887857",
    "official_title": "A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML)",
    "inclusion_criteria": "* Confirmation of the following for Acute Myeloid Leukemia (AML)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. ECOG 3 is allowed if participants are 18 to 74 years old with comorbidities\n* Agree to serial bone marrow aspirate/biopsies\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype\n* Received prior hypomethylating agent (HMA) therapy for myelodysplastic syndromes/Chronic myelomonocytic leukemia then develop AML within 4 months of discontinuing the HMA therapy\n* Prior history of malignancy unless the participant has been free of the disease for ≥ 1 year prior to the start of study treatment\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}